 |
11 Diseases |  |
38 Trials |
|
38 Trials |  |
2772 News |  |
| «12...27282930313233343536373839» |
- |||| Taltz (ixekizumab) / Eli Lilly, Second Xiangya Hospital of Central South University, Tremfya (guselkumab) / J&J
Video: This author video by @AndyBlauvelt details more about his team's RCT on ixekizumab vs guselkumab #dermatology #dermtwitter https://t.co/ir8vCDnMGB (Twitter) - Jun 12, 2020
- ||||| Taltz (ixekizumab) / Eli Lilly, Second Xiangya Hospital of Central South University, Tremfya (guselkumab) / J&J
Clinical: Wondering about biologic choice? In this RCT, @AndyBlauvelt et al compare ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis. Have a look at our 'What This Study Adds' summaries! https://t.co/nhEnR2gXwe (Twitter) - Jun 12, 2020
- |||| Tremfya (guselkumab) / J&J, Cosentyx (secukinumab) / Novartis
Clinical, Pricing: 85 new #psoriasis #Pubmed hits. Highlighting this paper @JanssenUS Cost per for #PASI 90 at 48 weeks was $89,960 for #guselkumab v $110,977 for #secukinumab, maintenance year $77,109 for guselkumab v. $88,781 for secukinumab. https://t.co/hFWL1T7bHO #dermtwitter @AADmember (Twitter) - Jun 11, 2020
- | Tremfya (guselkumab) / J&J
Trial completion date: GALAXI: A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease (clinicaltrials.gov) - Jun 11, 2020
P2/3, N=1900, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial completion date: Oct 2024 --> Jul 2028
- || Tremfya (guselkumab) / J&J
Clinical, Journal: Guselkumab efficacy after withdrawal is associated with suppression of serum IL-23-regulated IL-17 and IL-22 in psoriasis: VOYAGE 2 study. (Pubmed Central) - Jun 8, 2020
Increases in cytokine levels had poor predictive power for psoriasis reoccurrence as these increases lagged behind increases in PASI scores Upon guselkumab withdrawal, most patients lost clinical response and regained responses with retreatment. Correlation of IL-23 signaling serum cytokines increased with disease recurrence, supporting the role of IL-23 in expansion and maintenance of CD4+ Th17, Th22, and related CD8+ Tc cell subsets producing IL-17A, IL-17F, and IL-22.
- || Clinical, Review, Journal: Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. (Pubmed Central) - Jun 8, 2020
Other biologics inhibit cytokines such as the p40 subunit of the cytokines IL-12 and IL-13 (ustekinumab), IL-17 (secukinumab, ixekizumab, bimekizumab, and brodalumab), and the p19 subunit of IL-23 (guselkumab, tildrakizumab, risankizumab, and mirikizumab)...Oral treatments include traditional agents such as methotrexate, acitretin, cyclosporine, and the advanced small molecule apremilast, which is a phosphodiesterase 4 inhibitor...Topical therapies remain the cornerstone for treating mild psoriasis. Therapeutic advancements for moderate to severe plaque psoriasis include biologics that inhibit TNF-α, p40IL-12/23, IL-17, and p19IL-23, as well as an oral phosphodiesterase 4 inhibitor.
- |||| Tremfya (guselkumab) / J&J
So the million #euro question is will guselkumab work in ankylosis spondylitis? Is IL23 relevant beyond PsA spondylitis? RCT is needed - I bet yes @eular_org #EULAR2020 @RheumNow @CRASCRRheum @earlyarthritis (Twitter) - Jun 5, 2020
- || Tremfya (guselkumab) / J&J
Clinical, Journal: Immunogenicity of Guselkumab Is Not Clinically Relevant in Patients with Moderate-to-Severe Plaque Psoriasis. (Pubmed Central) - Jun 5, 2020
Through Week100, 8.5% of evaluable guselkumab-treated patients were ADA+. Neither ADA development nor guselkumab withdrawal and retreatment reduced systemic drug exposure or clinical efficacy or increased the occurrence of injection-site reactions.
- | Tremfya (guselkumab) / J&J
Biomarker, Enrollment change, Trial withdrawal: Biomarkers in Participants With Hidradenitis Suppurativa Receiving Guselkumab. (clinicaltrials.gov) - Jun 4, 2020
P1, N=0, Withdrawn, Sponsor: Rockefeller University
Neither ADA development nor guselkumab withdrawal and retreatment reduced systemic drug exposure or clinical efficacy or increased the occurrence of injection-site reactions. N=10 --> 0 | Not yet recruiting --> Withdrawn
- ||||| Taltz (ixekizumab) / Eli Lilly, Second Xiangya Hospital of Central South University, Tremfya (guselkumab) / J&J
Clinical: This head‐to‐head study by @AndyBlauvelt et al directly compares the efficacy and speed of response of ixekizumab and the IL‐23 inhibitor guselkumab in moderate‐to‐severe plaque #psoriasis. https://t.co/HrMrx8l9eo (Twitter) - Jun 4, 2020
- |||| Tremfya (guselkumab) / J&J
Nice surprise as IL23 Guselkumab works not only in PsA but axial PsA. Another Rx option also presented at @eular_org #EULAR2020 @CRASCRRheum @earlyarthritis (Twitter) - Jun 3, 2020
- Taltz (ixekizumab) / Eli Lilly, Second Xiangya Hospital of Central South University, Tremfya (guselkumab) / J&J
[VIRTUAL] Ixekizumab versus guselkumab: 24-week clinical responses and 4-week gene expression data () - May 31, 2020 - Abstract #SID2020SID_21;
A greater number of overexpressed genes were reduced by IXE than GUS at Weeks 1-4 (Week 1: 156 vs. 5; Week 2: 191 vs. 41; Week 4: 260 vs. 113). In conclusion, IXE was non-inferior to GUS in skin clearance but superior in clearing nails at Week 24, with no new safety signals, and IXE more rapidly reduced overexpressed psoriasis genes than GUS as early as Week 1.
- Humira (adalimumab) / Eisai, AbbVie, Tremfya (guselkumab) / J&J
[VIRTUAL] Important Measures for Psoriasis beyond PASI 100 – Patient-Reported Symptoms and Molecular Data from Patients Treated with Guselkumab or Adalimumab – A Sub-analysis from VOYAGE 1&2 () - May 27, 2020 - Abstract #AADVMX2020AAD-VMX_95;
- | Tremfya (guselkumab) / J&J
Journal: Psoriasis Drug Guselkumab Improved Psoriatic Arthritis Symptoms. (Pubmed Central) - May 27, 2020
In conclusion, IXE was non-inferior to GUS in skin clearance but superior in clearing nails at Week 24, with no new safety signals, and IXE more rapidly reduced overexpressed psoriasis genes than GUS as early as Week 1. No abstract available
- | Tremfya (guselkumab) / J&J
Trial suspension: PROTOSTAR: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants (clinicaltrials.gov) - May 27, 2020
P3, N=125, Suspended, Sponsor: Janssen Research & Development, LLC
No abstract available Recruiting --> Suspended
- Tremfya (guselkumab) / J&J
[VIRTUAL] INTEGRATED SAFETY RESULTS OF TWO PHASE-3 TRIALS OF GUSELKUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS THROUGH THE PLACEBO-CONTROLLED PERIODS (Poster View) - May 22, 2020 - Abstract #EULAR2020EULAR_4177;
There were no meaningful safety differences between the Q8W and Q4W groups, no significant safety issues identified when comparing GUS to PBO, and no safety signals with regards to infections, malignancy, and MACE. The safety profile of GUS Q4W and Q8W in PsA pts was generally consistent with that in the Phase 3 trials of GUS Q8W for psoriasis.
- Tremfya (guselkumab) / J&J
[VIRTUAL] EFFICACY AND SAFETY OF GUSELKUMAB, A MONOCLONAL ANTIBODY SPECIFIC TO THE P19-SUBUNIT OF INTERLEUKIN-23, THROUGH WEEK 52 OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY CONDUCTED IN BIOLOGIC-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS (Poster Tour) - May 22, 2020 - Abstract #EULAR2020EULAR_3357;
In biologic-naïve pts with active PsA, GUS elicited sustained improvements in joint & skin symptoms; inhibition of radiographic progression & improvements in physical function, quality of life & composite indices through W52. GUS safety in PsA was similar at W24 1 & W52 and consistent with GUS safety in psoriasis.
- Humira (adalimumab) / Eisai, AbbVie, Tremfya (guselkumab) / J&J
[VIRTUAL] FOUR-YEAR EFFICACY AND SAFETY OF GUSELKUMAB IN PSORIASIS PATIENTS WITH AND WITHOUT PSORIATIC ARTHRITIS: A POOLED ANALYSIS FROM VOYAGE 1 AND VOYAGE 2 () - May 22, 2020 - Abstract #EULAR2020EULAR_3223;
Table. Pooled GUS Response Rates
- Tremfya (guselkumab) / J&J
[VIRTUAL] GUSELKUMAB IMPROVED WORK PRODUCTIVITY AND DAILY ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM A PHASE 3 TRIAL () - May 22, 2020 - Abstract #EULAR2020EULAR_2593;
Pooled GUS Response Rates Improvement in overall work productivity and daily activity was greater with GUS versus PBO among pts with moderate-to-severe PsA, resulting in potential annual incremental economic gains.
- Tremfya (guselkumab) / J&J
[VIRTUAL] EFFECTS OF GUSELKUMAB, A MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO THE P19-SUBUNIT OF INTERLEUKIN-23, ON DACTYLITIS AND ENTHESITIS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: POOLED RESULTS THROUGH WEEK 24 FROM TWO PHASE 3 STUDIES () - May 22, 2020 - Abstract #EULAR2020EULAR_2256;
Resolution of dactylitis or enthesitis was significantly associated with clinically meaningful improvements in PsA joint & skin symptoms. Improved dactylitis scores correlated with improved skin symptoms and mental health; improved LEI scores correlated with improved physical function.
- Tremfya (guselkumab) / J&J
[VIRTUAL] COMPARATIVE EFFICACY OF GUSELKUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS () - May 22, 2020 - Abstract #EULAR2020EULAR_2250;
NMA results indicate that GUS is comparable to most targeted PsA treatments for improvement in arthritis, soft tissue damage, physical function, and safety outcomes. For PASI outcomes, GUS is highly likely to provide a greater benefit than other targeted PsA treatments.
- Tremfya (guselkumab) / J&J
[VIRTUAL] GUSELKUMAB DEMONSTRATED AN INDEPENDENT TREATMENT EFFECT ON FATIGUE AFTER ADJUSTMENT FOR CLINICAL RESPONSE (ACR20) IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM PHASE-3 TRIALS DISCOVER 1 & 2 (Poster View) - May 22, 2020 - Abstract #EULAR2020EULAR_2071;
For PASI outcomes, GUS is highly likely to provide a greater benefit than other targeted PsA treatments. In 2 phase-3 trials, treatment with GUS of patients with active PsA led to significant improvements compared to PBO in fatigue, including substantial effects on FACIT-Fatigue that were independent of the effects on ACR 20, especially for the q4W dosing group.
- Tremfya (guselkumab) / J&J
[VIRTUAL] GUSELKUMAB, AN IL-23 INHIBITOR THAT SPECIFICALLY BINDS TO THE IL23P19-SUBUNIT, FOR ACTIVE PSORIATIC ARTHRITIS: ONE YEAR RESULTS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF PATIENTS WHO WERE BIOLOGIC-NAÏVE OR TNFΑ INHIBITOR-EXPERIENCED (Poster Tour) - May 22, 2020 - Abstract #EULAR2020EULAR_1650;
In pts continuing in the study, improvements in skin symptoms, dactylitis, enthesitis, physical function & quality of life were also maintained through 1 year. GUS 100 mg Q4W & Q8W were safe and well-tolerated through study completion and consistent with GUS safety in PsO.
- Tremfya (guselkumab) / J&J
[VIRTUAL] GUSELKUMAB-TREATED PATIENTS ACHIEVED CLINICALLY MEANINGFUL IMPROVEMENT IN SYSTEMIC SYMPTOMS AS MEASURED WITH PROMIS INSTRUMENT: RESULTS FROM PHASE-3 PSORIATIC ARTHRITIS TRIAL DISCOVER 1 () - May 22, 2020 - Abstract #EULAR2020EULAR_1513;
P3
GUS 100 mg Q4W & Q8W were safe and well-tolerated through study completion and consistent with GUS safety in PsO. Active PsA pts treated with GUS achieved clinically meaningful reduction in symptoms and improvement in physical function and social participation vs PBO at W24.
- |||| Tremfya (guselkumab) / J&J
New P3 trial: A Study of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease (clinicaltrials.gov) - May 21, 2020
P3, N=25, Not yet recruiting, Sponsor: Janssen Pharmaceutical K.K.
- | Tremfya (guselkumab) / J&J
Trial completion date: A Study of Guselkumab in Participants With Familial Adenomatous Polyposis (clinicaltrials.gov) - May 20, 2020
P1b, N=72, Recruiting, Sponsor: Janssen Research & Development, LLC
Active PsA pts treated with GUS achieved clinically meaningful reduction in symptoms and improvement in physical function and social participation vs PBO at W24. Trial completion date: Dec 2021 --> Mar 2022
- ||| Tremfya (guselkumab) / J&J
Biomarker, New trial: An Explorative Psoriasis Biomarker Study (clinicaltrials.gov) - May 19, 2020
P=N/A, N=50, Not yet recruiting, Sponsor: Centre for Human Drug Research, Netherlands
- | Tremfya (guselkumab) / J&J
Trial completion date: GALAXI: A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease (clinicaltrials.gov) - May 14, 2020
P2/3, N=1900, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial completion date: Dec 2021 --> Mar 2022 Trial completion date: Mar 2025 --> Oct 2024
- Tremfya (guselkumab) / J&J, Cosentyx (secukinumab) / Novartis
Cost per Responder analysis of guselkumab versus secukinumab in obese patients using efficacy results from the ECLIPSE head-to-head clinical trial () - May 6, 2020 - Abstract #AMCP2020AMCP_248;
Sponsorship: This analysis was supported by Janssen Scientific Affairs, LLC. Amanda Teeple and Tim Fitzgerald are employees of Janssen Scientific Affairs LLC.
- Tremfya (guselkumab) / J&J
Guselkumab for Psoriatic Arthritis: Results from Systematic Literature Review and Network Meta-Analysis () - May 6, 2020 - Abstract #AMCP2020AMCP_247;
For PASI outcomes, GUS is highly likely to provide a greater benefit than most other PsA treatments. Sponsorship: Janssen Pharmaceuticals
- | Tremfya (guselkumab) / J&J
New P2 trial: ORCHID-LN: A Study of Guselkumab in Participants With Active Lupus Nephritis (clinicaltrials.gov) - May 5, 2020
P2, N=60, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- ||| Tremfya (guselkumab) / J&J
P2 data, P3 data, Journal: Use of dose-exposure-response relationships in Phase 2 and Phase 3 guselkumab studies to optimize dose selection in psoriasis. (Pubmed Central) - Apr 17, 2020
The 100-mg guselkumab q8w dose regimen, based on the dose-exposure-response relationship from the Phase 2 study, produced the target serum concentration associated with high-level efficacy in the majority of patients in Phase 3. Phase 3 data further confirmed that guselkumab 100mg q8w is the optimum dosing regimen for treating patients with moderate-to-severe psoriasis.
- | Tremfya (guselkumab) / J&J
Trial completion date: GALAXI: A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease (clinicaltrials.gov) - Apr 15, 2020
P2/3, N=1900, Recruiting, Sponsor: Janssen Research & Development, LLC
Phase 3 data further confirmed that guselkumab 100mg q8w is the optimum dosing regimen for treating patients with moderate-to-severe psoriasis. Trial completion date: Oct 2024 --> Mar 2025
- | Stelara (ustekinumab) / J&J
Journal: Anti-interleukin-12 and anti-interleukin-23 agents in Crohn's disease. (Pubmed Central) - Apr 14, 2020
Expert opinion: Data from literature have demonstrated that ustekinumab holds the potential to deserve a relevant role in the management of patients with CD thanks to several properties, including the fast onset of action, the long duration of efficacy, the favorable safety profile, the systemic anti-inflammatory effect, and the peculiar way of administration. Nonetheless, additional research is warranted to determine the real value of ustekinumab, as current data are not able to answer all the questions about its effectiveness in real-life practice, and the external validity of the available results is not absolute.
- | Humira (adalimumab) / Eisai, AbbVie, Tremfya (guselkumab) / J&J
Clinical, Journal: Consistent responses with guselkumab treatment in Asian and non-Asian patients with psoriasis: An analysis from VOYAGE 1 and VOYAGE 2. (Pubmed Central) - Apr 14, 2020
Median serum guselkumab concentrations over time were comparable between the populations. Comparable responses between the Asian and non-Asian populations in this analysis suggest that the overall efficacy, safety, and the resulting benefit/risk analyses from VOYAGE 1 and VOYAGE 2 are applicable to Asian populations.
- ||| Tremfya (guselkumab) / J&J
Clinical, P3 data, Clinical Trial,Phase III, Journal: Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. (Pubmed Central) - Apr 11, 2020
P3
Comparable responses between the Asian and non-Asian populations in this analysis suggest that the overall efficacy, safety, and the resulting benefit/risk analyses from VOYAGE 1 and VOYAGE 2 are applicable to Asian populations. Guselkumab demonstrated a favourable benefit-risk profile and might be an effective treatment option for patients with active psoriatic arthritis.
- ||| Tremfya (guselkumab) / J&J
Clinical, P3 data, Clinical Trial,Phase III, Journal: Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. (Pubmed Central) - Apr 11, 2020
P3
Guselkumab, a human monoclonal antibody that specifically inhibits IL-23 by binding the cytokine's p19 subunit, was efficacious and demonstrated an acceptable benefit-risk profile in patients with active psoriatic arthritis who were naive to treatment with biologics. These data support the use of selective inhibition of IL-23 to treat psoriatic arthritis.
- ||| Tremfya (guselkumab) / J&J
Clinical, P3 data, Journal: Efficacy and safety of guselkumab, administered with a novel patient-controlled injector (One-Press), for moderate-to-severe psoriasis: results from the phase 3 ORION study. (Pubmed Central) - Apr 10, 2020
P3
Guselkumab administered using the One-Press patient-controlled injector was efficacious and well-tolerated in moderate-to-severe psoriasis patients, consistent with previously reported Phase-3 studies of guselkumab administered using UltraSafe Plus. One-Press was highly acceptable to patients.
- | New P4 trial, Head-to-Head: BeNeBio: Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis (clinicaltrials.gov) - Apr 8, 2020
P4, N=244, Not yet recruiting, Sponsor: Radboud University
- || Tremfya (guselkumab) / J&J
Clinical, Journal: A Case Report of Successful Treatment of Crohn's Disease and Psoriasis With Guselkumab. (Pubmed Central) - Apr 5, 2020
One-Press was highly acceptable to patients. No abstract available
- | Stelara (ustekinumab) / J&J, Tremfya (guselkumab) / J&J
Trial completion date, Trial primary completion date: Study of Guselkumab and Ustekinumab Following a Single Intravenous or Subcutaneous Administration in Healthy Chinese Participants (clinicaltrials.gov) - Apr 2, 2020
P1, N=60, Recruiting, Sponsor: Janssen Research & Development, LLC
No abstract available Trial completion date: Jun 2020 --> Jan 2021 | Trial primary completion date: Mar 2020 --> Jan 2021
- || Stelara (ustekinumab) / J&J, Tremfya (guselkumab) / J&J
Clinical, Journal: Safety of guselkumab in hepatitis B virus infection. (Pubmed Central) - Mar 31, 2020
Less information is available regarding the use of pure IL-23 antagonists. Herein we discuss the successful treatment with guselkumab of a patient with HBV core antibody positivity, without evidence of HBV reactivation or other liver complications.
- | Journal, HEOR: The Budget Impact of Introducing Tildrakizumab to a United States Health Plan for Managing Moderate-to-Severe Plaque Psoriasis. (Pubmed Central) - Mar 30, 2020
Herein we discuss the successful treatment with guselkumab of a patient with HBV core antibody positivity, without evidence of HBV reactivation or other liver complications. The introduction of tildrakizumab with a 1% annual uptake over 5 years has the potential to reduce the cost of treating patients with moderate-to-severe plaque psoriasis for a US health plan.
- | Tremfya (guselkumab) / J&J
She is on Tremfya (Twitter) - Mar 17, 2020
- | Stelara (ustekinumab) / J&J, Fumaderm (dimethyl fumarate) / Biogen
Retrospective data, Review, Journal: Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response. (Pubmed Central) - Mar 10, 2020
There were differences in efficacy between treatments within the same class. Longer-term analyses are needed to understand differences between these drugs beyond induction in what is a life-long condition.
- | Journal: Biologics switch in psoriasis. (Pubmed Central) - Mar 8, 2020
Materials & We did a thorough systematic review from 'PubMed' and 'Embase', which includes new biologics such as IL-12/IL-23 antagonists, IL-17A antagonists and IL-23 antagonists. Results & New biologics such as IL-17 antagonist or IL-23 antagonist show greater responses in bio-experienced patients and could even be used for patients in whom previous treatments failed.
- Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J, Zaltrap (ziv-aflibercept IV) / Sanofi, Regeneron, Steglatro (ertugliflozin) / Pfizer, Merck (MSD)
[VIRTUAL] HTA BEST PRACTICE - NICE FAST TRACK APPROVALS- 2-YEAR REPORT CARD () - Mar 8, 2020 - Abstract #ISPOR2020ISPOR_1379;
This may reflect a lack of awareness amongst manufacturers, a low valuation of the incentives provided (faster appraisal and adoption) or a restriction due to the exceptional value for money criteria. Payers offering faster evaluations with reimbursement incentives for new therapies at comparable costs could offer a best-practice HTA process for incentivizing lower company pricing.
- [VIRTUAL] BUDGET IMPACT ANALYSIS OF IXEKIZUMAB, GUSELKUMAB, RISANKIZUMAB AND/OR SECUKINUMAB FOR MANAGEMENT OF MODERATE-TO-SEVERE PSORIASIS IN THE KINGDOM OF SAUDI ARABIA () - Mar 8, 2020 - Abstract #ISPOR2020ISPOR_79;
RESULTS : The study showed a minimal increase in the overall budget with all scenarios compared to the status-quo: an increase of Saudi Arabia Riyal (SAR) 1.3 million (0.4%) in scenario 1, SAR 1.5 million (0.5%) in scenario 2, SAR 2.1 million (0.7%) in scenario 3 and SAR 2.4 million (0.8%) in scenario 4 over five-year time horizon. CONCLUSIONS : The introduction of advanced biologics in the KSA MoH formulary for the management of moderate-to-severe psoriasis patients could minimally increase the MoH budget.
- [VIRTUAL] BIOLOGIC THERAPIES FOR MODERATE-TO-SEVERE PSORIASIS- COST PER RESPONDER ANALYSIS CONSIDERING PRIVATE HEALTHCARE SYSTEM IN BRAZIL () - Mar 8, 2020 - Abstract #ISPOR2020ISPOR_61;
Comparative cost-effectiveness of risankizumab, adalimumab, etanercept, guselkumab, infliximab, ixekizumab, secukinumab, and ustekinumab was evaluated for the Brazilian private healthcare system using a cost-per-responder analysis based on PASI score reduction. Among the evaluated biologic therapies, risankizumab was associated with lowest cost-per-responder in all analyzed PASI outcomes, with more pronounced difference in higher PASI responses, considering Brazilian private healthcare system.
- Tremfya (guselkumab) / J&J
[VIRTUAL] EFFICACY OF GUSELKUMAB, A MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO THE P19-SUBUNIT OF IL-23, ON ENDPOINTS RELATED TO AXIAL INVOLVEMENT IN PATIENTS WITH ACTIVE PSA WITH IMAGING-CONFIRMED SACROILIITIS: WEEK-24 RESULTS FROM TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES (Tan) - Mar 4, 2020 - Abstract #EULAR2020EULAR_540;
Table. Efficacy of GUS in PsA patients with axial involvement at week 24.